Neurogene Inc. NGNE
Updated: 10 Aug 2026
No signal published yet
We already track Neurogene and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Neurogene Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Neurogene free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 1, 2026, Neurogene announced positive long-term Phase 1/2 clinical data for NGN-401 in Rett syndrome and priced a $125 million public offering. Earlier in June 2026, the company completed patient dosing in its Embolden registrational trial.
What Firelda Watch includes for Neurogene Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Neurogene Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Neurogene free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more